Renovacare, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020
August 13, 2020 at 04:19 pm EDT
Share
RenovaCare, Inc. announced earnings results for the second quarter ended June 30, 2020. For the second quarter, the company announced operating loss was USD 3.044 million compared to USD 643,528 a year ago. Net loss was USD 3.011 million compared to USD 547,504 a year ago. Basic loss per share from continuing operations was USD 0.03 compared to USD 0.01 a year ago. For the half year, operating loss was USD 4.272 million compared to USD 1.247 million a year ago. Net loss was USD 4.186 million compared to USD 1.066 million a year ago. Basic loss per share from continuing operations was USD 0.05 compared to USD 0.01 a year ago.
RenovaCare, Inc. is a clinical-stage biotechnology company. The Company is focused on developing autologous (self-donated) stem cell therapies for the regeneration of human organs. The Company through its wholly owned subsidiary, RenovaCare Sciences Corp. is focusing on the research, development and commercialization of autologous (using a patientâs own cells) cellular therapies that can be used for medical and aesthetic applications. The Companyâs CellMist System is a cell isolation procedure that enzymatically renders stem cells from the patientâs own skin or other tissues. The resulting stem cell suspension is administered topically from the Companyâs novel solution sprayer device (the SkinGun) as a cell therapy for wounds including burns to facilitate healing. Its SkinGun spray device is an advanced technology, using a gentle positive-pressure air stream to spray the CellMist Solution onto wounds.
RENOVACARE, INC. 
